Skip to main content

Compare Stocks

Date Range: 

 Bolt BiotherapeuticsFinch Therapeutics GroupOxford BiomedicaPharming GroupiTeos Therapeutics
SymbolNASDAQ:BOLTNASDAQ:FNCHLON:OXBNASDAQ:PHARNASDAQ:ITOS
Price Information
Current Price$18.79$12.04GBX 1,004$12.11$24.48
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score1.32.01.00.01.9
Analysis Score3.53.52.50.03.5
Community Score2.85.02.50.03.7
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.01.7
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$41.00$29.33GBX 1,140N/A$47.33
% Upside from Price Target118.20% upside143.63% upside13.55% upsideN/A93.36% upside
Trade Information
Market Cap$682.60 million$567.63 million£827.35 million$776.60 million$859.27 million
BetaN/AN/AN/AN/AN/A
Average Volume267,256144,444157,3187,176260,110
Sales & Book Value
Annual RevenueN/AN/A£87.73 millionN/AN/A
Price / SalesN/AN/A9.43N/AN/A
CashflowN/AN/AGBX 56.31 per shareN/AN/A
Price / CashN/AN/A17.83N/AN/A
Book ValueN/AN/AGBX 137 per shareN/AN/A
Price / BookN/AN/A0.07N/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AGBX (7.80)N/AN/A
Trailing P/E Ratio0.000.00N/A0.000.00
Forward P/E Ratio201.83N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A12.28%N/AN/A
Current RatioN/AN/A2.06%N/AN/A
Quick RatioN/AN/A1.88%N/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/A71.07%
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees6513167326262
Shares Outstanding36.33 million47.15 million82.41 million64.13 million35.10 million
Next Earnings Date8/12/2021 (Estimated)8/12/2021 (Estimated)N/AN/A8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
iTeos Therapeutics (NASDAQ:ITOS) Releases Quarterly  Earnings Results, Beats Expectations By $0.09 EPSiTeos Therapeutics (NASDAQ:ITOS) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
americanbankingnews.com - May 14 at 7:52 PM
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Rating of "Buy" by BrokeragesiTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Rating of "Buy" by Brokerages
americanbankingnews.com - May 14 at 10:56 AM
ITeos Therapeutics Inc to Host Earnings CallITeos Therapeutics Inc to Host Earnings Call
finance.yahoo.com - May 13 at 8:40 PM
iTeos Reports First Quarter 2021 Financial Results and Provides Business UpdateiTeos Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 13 at 8:40 PM
HC Wainwright Initiates Coverage on iTeos Therapeutics (NASDAQ:ITOS)HC Wainwright Initiates Coverage on iTeos Therapeutics (NASDAQ:ITOS)
americanbankingnews.com - May 11 at 8:37 AM
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expected to Post Earnings of -$0.48 Per ShareiTeos Therapeutics, Inc. (NASDAQ:ITOS) Expected to Post Earnings of -$0.48 Per Share
americanbankingnews.com - May 10 at 7:16 AM
iTeos Therapeutics (ITOS) to Release Quarterly Earnings on ThursdayiTeos Therapeutics (ITOS) to Release Quarterly Earnings on Thursday
americanbankingnews.com - May 8 at 10:21 AM
iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021
finance.yahoo.com - May 6 at 7:38 PM
iTeos Therapeutics (NASDAQ:ITOS) Now Covered by Analysts at HC WainwrightiTeos Therapeutics (NASDAQ:ITOS) Now Covered by Analysts at HC Wainwright
americanbankingnews.com - May 5 at 7:18 AM
iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of DirectorsiTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors
finance.yahoo.com - May 3 at 7:07 PM
Iteos Therapeutics Inc (ITOS)Iteos Therapeutics Inc (ITOS)
investing.com - May 1 at 7:49 AM
Were Not Worried About iTeos Therapeutics (NASDAQ:ITOS) Cash BurnWe're Not Worried About iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn
finance.yahoo.com - April 26 at 9:59 AM
iTeos Therapeutics InciTeos Therapeutics Inc
bloomberg.com - April 25 at 8:01 AM
Companies Like iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Invest In GrowthCompanies Like iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Invest In Growth
nasdaq.com - April 23 at 8:35 AM
-$0.48 EPS Expected for iTeos Therapeutics, Inc. (NASDAQ:ITOS) This Quarter-$0.48 EPS Expected for iTeos Therapeutics, Inc. (NASDAQ:ITOS) This Quarter
americanbankingnews.com - April 22 at 4:22 PM
 Brokerages Anticipate iTeos Therapeutics, Inc. (NASDAQ:ITOS) Will Announce Earnings of -$0.48 Per Share Brokerages Anticipate iTeos Therapeutics, Inc. (NASDAQ:ITOS) Will Announce Earnings of -$0.48 Per Share
americanbankingnews.com - April 22 at 4:22 PM
 Brokerages Anticipate iTeos Therapeutics, Inc. (NASDAQ:ITOS) to Post -$0.48 Earnings Per Share Brokerages Anticipate iTeos Therapeutics, Inc. (NASDAQ:ITOS) to Post -$0.48 Earnings Per Share
americanbankingnews.com - April 22 at 4:22 PM
iTeos Therapeutics (NASDAQ:ITOS) Sees Unusually-High Trading VolumeiTeos Therapeutics (NASDAQ:ITOS) Sees Unusually-High Trading Volume
americanbankingnews.com - April 21 at 11:43 AM
Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21
ca.finance.yahoo.com - April 11 at 11:08 PM
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its ...iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its ...
apnews.com - April 10 at 12:43 PM
iTeos Therapeutics Inc. [ITOS] moved down -14.49: Why It’s ImportantiTeos Therapeutics Inc. [ITOS] moved down -14.49: Why It’s Important
dbtnews.com - March 25 at 10:03 PM
12-month price target for iTeos Therapeutics, Inc. (NASDAQ:ITOS) now sits at $5012-month price target for iTeos Therapeutics, Inc. (NASDAQ:ITOS) now sits at $50
marketingsentinel.com - March 25 at 12:02 PM
iTeos Therapeutics Inc.: iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateiTeos Therapeutics Inc.: iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
finanznachrichten.de - March 24 at 7:24 PM
iTeos to Present at Upcoming Investor Conferences in MarchiTeos to Present at Upcoming Investor Conferences in March
finance.yahoo.com - February 23 at 9:43 AM
iTeos to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceiTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 17 at 11:55 AM
DateCompanyBrokerageAction
4/13/2021Bolt BiotherapeuticsSVB LeerinkBoost Price Target
3/8/2021Bolt BiotherapeuticsMorgan StanleyInitiated Coverage
3/8/2021Bolt BiotherapeuticsGuggenheimInitiated Coverage
3/8/2021Bolt BiotherapeuticsStifel NicolausInitiated Coverage
4/19/2021Finch Therapeutics GroupBank of AmericaInitiated Coverage
4/19/2021Finch Therapeutics GroupJefferies Financial GroupInitiated Coverage
4/19/2021Finch Therapeutics GroupEvercore ISIInitiated Coverage
4/15/2021Oxford BiomedicaLiberum CapitalReiterated Rating
7/31/2020Oxford BiomedicaPeel HuntReiterated Rating
5/11/2021iTeos TherapeuticsHC WainwrightInitiated Coverage
3/25/2021iTeos TherapeuticsWedbushBoost Price Target
10/7/2020iTeos TherapeuticsRobert W. BairdInitiated Coverage
8/18/2020iTeos TherapeuticsJPMorgan Chase & Co.Initiated Coverage
8/18/2020iTeos TherapeuticsPiper SandlerInitiated Coverage
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.